RU2328283C2 - Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv - Google Patents

Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv Download PDF

Info

Publication number
RU2328283C2
RU2328283C2 RU2003132687/14A RU2003132687A RU2328283C2 RU 2328283 C2 RU2328283 C2 RU 2328283C2 RU 2003132687/14 A RU2003132687/14 A RU 2003132687/14A RU 2003132687 A RU2003132687 A RU 2003132687A RU 2328283 C2 RU2328283 C2 RU 2328283C2
Authority
RU
Russia
Prior art keywords
diabetes
inhibitor
treatment
day
inhibitors
Prior art date
Application number
RU2003132687/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2003132687A (ru
Inventor
Пьер БРОКА (GB)
Пьер БРОКА
Беатрис СЮДР (CH)
Беатрис СЮДР
Мишель Л. ОБЕР (CH)
Мишель Л. ОБЕР
Original Assignee
Ферринг Бв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ферринг Бв filed Critical Ферринг Бв
Publication of RU2003132687A publication Critical patent/RU2003132687A/ru
Application granted granted Critical
Publication of RU2328283C2 publication Critical patent/RU2328283C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
RU2003132687/14A 2001-04-11 2002-04-10 Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv RU2328283C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0109146.1A GB0109146D0 (en) 2001-04-11 2001-04-11 Treatment of type 2 diabetes
GB0109146.1 2001-04-11

Publications (2)

Publication Number Publication Date
RU2003132687A RU2003132687A (ru) 2005-04-10
RU2328283C2 true RU2328283C2 (ru) 2008-07-10

Family

ID=9912727

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003132687/14A RU2328283C2 (ru) 2001-04-11 2002-04-10 Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv

Country Status (22)

Country Link
US (1) US20040209891A1 (US06780888-20040824-C00057.png)
EP (1) EP1377278B1 (US06780888-20040824-C00057.png)
JP (1) JP2004525179A (US06780888-20040824-C00057.png)
KR (1) KR20040025915A (US06780888-20040824-C00057.png)
CN (1) CN1248683C (US06780888-20040824-C00057.png)
AT (1) ATE344029T1 (US06780888-20040824-C00057.png)
AU (1) AU2002244860B2 (US06780888-20040824-C00057.png)
CA (1) CA2443229A1 (US06780888-20040824-C00057.png)
CZ (1) CZ20032927A3 (US06780888-20040824-C00057.png)
DE (1) DE60215787T2 (US06780888-20040824-C00057.png)
GB (1) GB0109146D0 (US06780888-20040824-C00057.png)
HK (1) HK1059213A1 (US06780888-20040824-C00057.png)
HU (1) HUP0303876A3 (US06780888-20040824-C00057.png)
IL (1) IL157821A0 (US06780888-20040824-C00057.png)
MX (1) MXPA03009224A (US06780888-20040824-C00057.png)
NO (1) NO20034549D0 (US06780888-20040824-C00057.png)
NZ (1) NZ528172A (US06780888-20040824-C00057.png)
PL (1) PL366633A1 (US06780888-20040824-C00057.png)
RU (1) RU2328283C2 (US06780888-20040824-C00057.png)
UA (1) UA76452C2 (US06780888-20040824-C00057.png)
WO (1) WO2002083109A1 (US06780888-20040824-C00057.png)
ZA (1) ZA200307156B (US06780888-20040824-C00057.png)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002531A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
GB0125445D0 (en) * 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
AU2002952946A0 (en) * 2002-11-27 2002-12-12 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070149451A1 (en) * 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
JP2007511487A (ja) 2003-11-17 2007-05-10 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼｉｖ阻害剤の使用
US20080038341A1 (en) 2004-01-20 2008-02-14 James Kowalski Direct Compression Formulation And Process
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102134229B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
WO2005118555A1 (en) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006012395A2 (en) * 2004-07-23 2006-02-02 Susan Marie Royalty Peptidase inhibitors
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
ZA200708179B (en) 2005-04-22 2009-12-30 Alantos Pharmaceuticals Holding Inc Dipeptidyl peptidase-IV inhibitors
KR20080030652A (ko) * 2005-08-11 2008-04-04 에프. 호프만-라 로슈 아게 Ｄｐｐ-ｉｖ 억제제를 포함하는 약학 조성물
PL1942898T5 (pl) 2005-09-14 2014-10-31 Takeda Pharmaceuticals Co Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
FR2938999B1 (fr) * 2008-11-24 2011-07-01 Oreal Procede de preparation d'un parfum au sein d'un systeme comportant une pluralite de terminaux interactifs de formulation de parfums et un serveur agence pour echanger des donnees avec la pluralite de terminaux
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
EP1189629B1 (en) * 1999-02-10 2010-09-29 Curis, Inc. Peptide yy (pyy) for treating glucose metabolic disorders
GB9906714D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6107317A (en) * 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
JP2003535034A (ja) * 1999-11-12 2003-11-25 ギルフォード ファーマシューティカルズ インコーポレイテッド ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
KR20080067009A (ko) * 2000-03-31 2008-07-17 프로시디온 리미티드 디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOLST J.J. et al. Inhibition of the activity of Dipeptidyl-peptidase IV as a treatment for type 2 diabetes // Diabetes, New York, vol.47, November 1998, pp.1663-1670. *
Клиническая эндокринология/Под ред. проф. Н.Т.Старковой. - М.: Медицина, 1991, с.197-198, 205, 231, 235-236. Лейкок Джон Ф.и др. Основы эндокринологии, пер. с англ. - М.: Медицина, 2000, подп. в печ. 06.12.1999, с.381, 383-384, 387-388. *

Also Published As

Publication number Publication date
HK1059213A1 (en) 2004-06-25
MXPA03009224A (es) 2004-01-29
HUP0303876A2 (hu) 2004-03-01
ATE344029T1 (de) 2006-11-15
KR20040025915A (ko) 2004-03-26
DE60215787D1 (de) 2006-12-14
CA2443229A1 (en) 2002-10-24
PL366633A1 (en) 2005-02-07
NO20034549L (no) 2003-10-09
CN1248683C (zh) 2006-04-05
NZ528172A (en) 2004-09-24
US20040209891A1 (en) 2004-10-21
JP2004525179A (ja) 2004-08-19
CN1501796A (zh) 2004-06-02
HUP0303876A3 (en) 2005-06-28
ZA200307156B (en) 2004-06-04
EP1377278B1 (en) 2006-11-02
RU2003132687A (ru) 2005-04-10
GB0109146D0 (en) 2001-05-30
IL157821A0 (en) 2004-03-28
DE60215787T2 (de) 2007-08-30
EP1377278A1 (en) 2004-01-07
WO2002083109A1 (en) 2002-10-24
UA76452C2 (en) 2006-08-15
AU2002244860B2 (en) 2006-11-16
NO20034549D0 (no) 2003-10-09
CZ20032927A3 (cs) 2004-06-16

Similar Documents

Publication Publication Date Title
RU2328283C2 (ru) Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv
AU2002244860A1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
US5393772A (en) Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
KR100967070B1 (ko) 아세트산 아닐리드 유도체를 유효성분으로 하는 과활동방광 치료제
EP1303304B1 (en) Pharmaceutical combinations for treatment and prevention of diabetes mellitus
IL139862A (en) History of thiazolidine or pyroladine as effects of dipheptidyl peptides IV and pharmaceutical preparations containing them
KR20090038908A (ko) 대사 장애의 조합 치료
KR20100134032A (ko) 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
BRPI0614732A2 (pt) composição farmacêutica que compreende um inibidor de dpp-iv, uso de um inibidor de dpp-iv e método para o tratamento de enfermidades associadas com nìveis de glicose sanguìnea elevados
EA015382B1 (ru) Применение рофлумиласта для лечения сахарного диабета типа 2
CA2724133A1 (en) Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine
RU2012110592A (ru) Соединения и способ снижения мочевой кислоты
JP2005526696A5 (US06780888-20040824-C00057.png)
JP2009515877A (ja) Ｃｎｓ障害を処置するための組成物および方法
JP2007529545A (ja) ダウン症候群の治療法
WO1998027982A1 (fr) Composition contenant de l'acide ascorbique
KR20050090447A (ko) 당뇨병 치료용 키뉴레닌 3-하이드록실라제 저해제
US9050347B2 (en) 1,2,4-oxadiazole derivatives as drugs modulating the GLP-1 peptide receptor
AU2004269923B2 (en) Use of PDE4 inhibitors for the treatment of diabetes mellitus
KR20070104913A (ko) 2형 당뇨병의 예방 및 치료에 사용될 수 있는 약제의제조를 위한 리모나반트의 용도
JPH0959155A (ja) コレステリルエステル転送反応阻害剤
JPWO2004082683A1 (ja) 慢性皮膚疾患の治療および／または予防剤
AU2003262286B2 (en) Novel Effectors of Dipeptidyl Peptidase IV
EP1323419A1 (en) Airway mucus secretion inhibitors
WO1996031479A1 (en) Novel heterocyclic compounds

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080411